Piramal Pharma Limited released its sustainability report for FY26, disclosing a 22.6% reduction in Scope 1 and Scope 2 greenhouse gas emissions against the FY22 baseline. The company achieved its lowest-ever emissions levels while generating total revenue of ₹8,869 crore.

The report covers operations from April 1, 2025, to March 31, 2026, across Piramal Pharma Solutions, Piramal Critical Care, and Piramal Consumer Healthcare. DNV Business Assurance India Pvt Ltd provided independent limited assurance on key disclosures.

Financial and Operational Performance

Revenue from operations stood at ₹8,869.08 crore, down from ₹9,151.18 crore in FY25. EBITDA was ₹1,134.92 crore, compared to ₹1,579.64 crore in the prior year. The company reported a net loss of ₹325.94 crore, reversing a net profit of ₹91.13 crore in FY25.

Interest payments fell to ₹296.35 crore from ₹438.40 crore. Employee wages and benefits rose to ₹2,415.92 crore from ₹2,307.47 crore.

Environmental Impact

Renewable sources met 41% of total energy consumption. Total energy mix reached 14,20,663 GJ, with renewable/green energy contributing 5,80,730 GJ. Green fuels accounted for 52% of the overall fuel mix.

Scope 1 emissions were 47,796 tCO₂e, while location-based Scope 2 emissions were 92,626 tCO₂e. Market-based Scope 2 emissions were 62,412 tCO₂e. Scope 3 emissions totaled 6,48,835 tCO₂e.

What the Numbers Show

Scope 3 emissions represent the vast majority of the company's carbon footprint. At 6,48,835 tCO₂e, indirect value chain emissions are nearly six times higher than the combined 1,40,422 tCO₂e of direct and location-based indirect emissions. This concentration highlights that future decarbonisation efforts will depend heavily on supplier engagement rather than just internal operational changes.

Social and Governance Metrics

The company maintained zero data breaches and zero fatalities over the last five years. Women constitute 20.1% of the global workforce and 30% of the Board. Customer satisfaction scores were 85% for Piramal Pharma Solutions and 87% for Piramal Critical Care.

CSR expenditure rose to ₹8.98 crore from ₹5.34 crore, impacting approximately 1.8 million people across 112 aspirational districts.

Piramal Pharma has completed the acquisition of an additional 40.67% stake in Yapan Bio Private Limited for ₹76 crore, raising its total shareholding in the contract development and manufacturing organization (CDMO) to 74%. The transaction, which involved the purchase of 1,46,400 equity shares of ₹10 each, changes Yapan Bio's status from an associate company to a subsidiary.

Acquisition details

The following table summarises the key parameters of the transaction:

The acquisition was disclosed under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, on August 18, 2026. It follows a previous communication dated August 10, 2026, regarding the exercise of a call option for the additional equity stake.

Yapan Bio financials and operations

Yapan Bio, incorporated on October 11, 2019, specializes in process development, characterization, and Phase I/II GMP manufacturing services for vaccines and biologics. The company’s revenue from operations showed significant growth followed by a contraction in the most recent fiscal year:

• FY24: ₹26.91 crore
• FY25: ₹54.40 crore
• FY26: ₹26.34 crore

With this acquisition, Piramal Pharma will fully embed Yapan Bio's advanced large molecule capabilities into its integrated service offering. This move is expected to enable the company to develop and scale complex biologic therapies with greater efficiency. The promoter group of Piramal Pharma is deemed to be indirectly interested in Yapan Bio through the company's investment.